vialroom

#retatrutide 2025-08-30

Saturday13 messages5 participantstimes are UTC
Highlights from this day
  • sulphur_burp — nobody should read my log as a plan, im recording what i did and thats all it is 12:17
  • sulphur_burp — held at 2.5 for 18 months and it never plateaued for me, which i cant explain 12:21
  • pbs_pip — Medutest came back 99.2 on one lot and 98.1 on the next from the same Homopeptide, both fine, n of 1 obviously 12:59
  • VialBot — Verification log updated: QYB — evidence added, status unchanged. 15:05
SB

nobody should read my log as a plan, im recording what i did and thats all it is

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.
II

GI was about the same as tirzepatide for me, the difference was how fast it arrived

SB

held at 2.5 for 18 months and it never plateaued for me, which i cant explain

baseline  58
wk 2      61
wk 4      64
wk 6      67
wk 8      66
wk 10     65   (held dose from wk 7)
PP

Medutest came back 99.2 on one lot and 98.1 on the next from the same Homopeptide, both fine, n of 1 obviously

II

the honest position is this has less human evidence behind it than anything else discussed here

PP

sorry to jump in there is no long term safety data, phase 2 and an ongoing phase 3 programme is what exists

SI

is the phase 2 dosing anywhere near what people here run

triple agonist yeah

SB

i was wrong to call the heart rate a non issue last year, enough people logged it that i changed my mind, we shall see

VB

Verification log updated: QYB — evidence added, status unchanged.

SB

im at 7.5 and the appetite effect is stronger than i expected, normal

anyone tracking blood pressure alongside the heart rate

🧊2❤️5